Report: Here's how Houston ranks in terms of its gender pay gap

by the numbers

It's 2024 and women are still making less money than men. Photo by LinkedIn Sales Solutions on Unsplash

It's 2024 and women are still making less money than men, thus keeping the unfortunate reality of the wage gap alive. But at least in Houston, the wage gap isn't as bad as other Texas cities, according to a new earnings study by Chamber of Commerce.

Houston ranked No. 142 on the list, which examined earnings for full-time workers in 170 of the most populous cities in the United States.

The study found that, in 2024, men in Houston are currently making $4,474 more than women — a figure that's significantly lower than the national wage gap, which is a little over $11,000.

The U.S. city with the worst gender pay gap is none other than Frisco, a Dallas suburb. Men in Frisco are currently making a staggering $52,216 more than women, which is more than $12,000 more than the gap in 2023.

Also in North Texas, McKinney remained in the No. 5 spot for the second consecutive year. McKinney men make $24,568 more than women, which is a $4,400 decrease year-over-year. Plano's gender wage gap has worsened since 2023: The Dallas suburb is now listed among the top 10 worst pay gaps in the U.S., climbing to No. 6. The study says the Plano's wage gap is now $23,415, or nearly $2,300 more than last year.

Statewide gender pay gap

Chamber of Commerce found that Texas' gender pay gap has increased since last year; The 2023 study found that women made nearly $11,000 less than men, and that discrepancy has widened in 2024 to nearly $12,000.

However, Texas' ranking has improved 10 spots from No. 29 last year to No. 19 this year.

For added context, New Hampshire has the No. 1 worst pay gap in the nation, with men making over $18,000 more than women.

Other Texas cities that earned spots in the report are:

     
  • No. 20 – Amarillo
  • No. 22 – Laredo
  • No. 24 – Austin
  • No. 30 – Corpus Christi
  • No. 31 – Pasadena
  • No. 33 – Irving
  • No. 52 – Lubbock
  • No. 59 – El Paso
  • No. 65 – Grand Prairie
  • No. 81 – Fort Worth
  • No. 118 – Dallas
  • No. 121 – San Antonio
  • No. 125 – Arlington
  • No. 167 – Brownsville
  • No. 168 – Garland

------

This article originally ran on CultureMap.

A new study finds how Houston — and other Texas cities — rank in terms of the pay gap between male and female workers. Photo via Getty Images

How Houston stacks up when it comes to its gender pay gap

mind the gap

Pi wasn't the only thing celebrated yesterday on March 14. Equal Pay Day is also celebrated on the same day — a day to examine the decades of advocacy to extinguish the pay gap between men and women.

Unfortunately, nationwide the gap is still large. The latest Census Bureau says women make 18 percent less money than men do. We know the numbers for Texas and several of its cities, thanks to a new study by small biz experts Chamber of Commerce. They investigated the earnings for full-time workers in 170 of the most populous cities in the United States.

The analysis found that Texas has the 29th largest pay gap out of all 50 states, with women making nearly $11,000 less than men. Texas women can be glad they don’t live in Wyoming, which has the largest pay gap of the states at almost $19,000.

The city with the largest gender pay gap in the United States is Sunnyvale, California, home to Silicon Valley, with an earnings difference of $40,584 between men and women. Actually, California cities make up half of the top 10 largest gender pay gaps.

Texas, however, has two towns in the top 10. Coming in at No. 2 is Frisco and McKinney lands at No. 5. Frisco men make nearly $40,000 more than women, while McKinney men make $29,000 more than women. Just outside the top 10 is Plano at No. 12, with their gender pay gap adding up to $20,736.

How does Houston fair? Not too shabby, actually. The Bayou City landed at the No. 114 spot out of 170 of the most-populated cities in the U.S. Dallas actually has the smallest gender pay gap in Texas, coming in at No. 166 with just $192 between full-time working men and women.

Here's how the rest of Texas ranks:

  • No. 13 – Austin
  • No. 25 – Pasadena
  • No. 30 – Lubbock
  • No. 45 – Fort Worth
  • No. 70 – Irving
  • No. 71 – Corpus Christi
  • No. 74 – San Antonio
  • No. 89 – Arlington
  • No. 93 – Grand Prairie
  • No 97 – El Paso
  • No. 101 – Laredo
  • No. 110 – Amarillo
  • No. 125 – Brownsville
  • No. 134 – Garland

The full study can be found on chamberofcommerce.org.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings